Table of Contents

company-logo

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Noxopharm Dividend Announcement

• Noxopharm does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Noxopharm dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Noxopharm Dividend History

Noxopharm Dividend Yield

Noxopharm current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Noxopharm stock? Use our calculator to estimate your expected dividend yield:

Noxopharm Financial Ratios

P/E ratio-8.57
PEG ratio-0.09
P/B ratio5.58
ROE-59.29%
Payout ratio0.00%
Current ratio3.83
Quick ratio5.72
Cash Ratio1.86

Noxopharm Dividend FAQ

Does Noxopharm stock pay dividends?
Noxopharm does not currently pay dividends to its shareholders.
Has Noxopharm ever paid a dividend?
No, Noxopharm has no a history of paying dividends to its shareholders. Noxopharm is not known for its dividend payments.
Why doesn't Noxopharm pay dividends?
There are several potential reasons why Noxopharm would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Noxopharm ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Noxopharm has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Noxopharm a dividend aristocrat?
Noxopharm is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Noxopharm a dividend king?
Noxopharm is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Noxopharm a dividend stock?
No, Noxopharm is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Noxopharm stocks?
To buy Noxopharm you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Noxopharm stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.